SCHEDULE 13G: BlackRock Discloses 5.5% Passive Stake in Cidara Therapeutics

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.5% beneficial ownership stake in Cidara Therapeutics, Inc. as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 1,107,668 shares of Cidara Therapeutics, Inc. common stock.
• This ownership represents 5.5% of the total outstanding common shares of Cidara Therapeutics, Inc.
• BlackRock holds sole voting power over 1,081,502 shares and sole dispositive power over 1,107,668 shares.
• The filing was made under Rule 13d-1(b), indicating a passive investment strategy.
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Cidara Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. The presence of a large institutional investor like BlackRock could be interpreted positively by some, but the filing itself does not convey explicit positive or negative sentiment regarding the issuer's performance or outlook.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Key Dates

Keywords

BlackRock, Cidara Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment